SlideShare a Scribd company logo
Pharm-Immunology-14 & 15 Immunology of Cancer & Transplants Hussein
Introduction ,[object Object],[object Object],[object Object]
Objectives ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Evidence supporting the concept that the immune system reacts against tumors ,[object Object],Fig. 10-1
Immune Recognition ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CALLA (CD10) ,[object Object],[object Object],[object Object],[object Object]
Immune Responses ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Specificity of tumor immunity ,[object Object],[object Object],[object Object],[object Object],[object Object],tum -
Tc specificity ,[object Object],[object Object],[object Object],[object Object]
Immune Responses ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Immune Responses ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Immune Responses ,[object Object],[object Object],[object Object]
Immunosurveillance ,[object Object],[object Object],[object Object],[object Object]
Evasion Of The Immune System/Escape mechanisms ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
How tumors evade immune responses? ,[object Object],[object Object],[object Object],[object Object],[object Object],Fig 10-4
Tumor Ag presentation to T cells in 3 ways: ,[object Object],[object Object],[object Object],TCR
Cancer Immunotherapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Strategies for enhancing antitumor immune responses ,[object Object],[object Object],[object Object],[object Object],Fig 10-5
Pulsing of dendritic cells
 
Antihelminthic, immune Response enhancer
Augmenting the host response by specific immunotherapy
 
Therapeutic modification of mAbs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
In vitro purging of tumor-infiltrated bone marrow ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Immunodiagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
NORMAL RANGE  
Immune Response Against Transplant ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Types of grafts ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Types of Grafts ,[object Object],[object Object],[object Object],[object Object],[object Object]
Transplantation Laws ,[object Object],[object Object],[object Object],[object Object],[object Object]
Evidence indicating that the rejection of tissue transplants is an immune reaction ,[object Object]
Recognition of allogeneic MHC molecules by T lymphocytes. ,[object Object],[object Object],[object Object],[object Object]
Direct and indirect recognition of alloantigens ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Graft APC
Mechanisms of graft rejection: Hyperacute rejections ,[object Object],[object Object],[object Object],[object Object]
Mechanisms of graft rejection: Acute rejection  ,[object Object],[object Object],[object Object]
Chronic Graft Rejection ,[object Object],[object Object],[object Object],[object Object]
Mechanisms of graft rejection: Chronic rejection ,[object Object],[object Object]
 
Graft Rejection Displays Immunological Memory ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Graft-versus-Host Reaction (GvHR) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Mixed lymphocyte reaction ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ABO blood groups & blood transfusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatments for graft rejection ,[object Object],[object Object],Brendan Doran ( Tacrolimus )
                                                                                                                                                                                     

More Related Content

What's hot

Immunological tolerance
Immunological toleranceImmunological tolerance
IMMUNE RESPONSE TO TUMORS
IMMUNE RESPONSE TO TUMORSIMMUNE RESPONSE TO TUMORS
IMMUNE RESPONSE TO TUMORS
Saajida Sultaana
 
Transplantation immunology
Transplantation immunology Transplantation immunology
Transplantation immunology
Kannan Iyanar
 
Tumor antigen
Tumor antigenTumor antigen
Tumor antigen
Swathi Prabakar
 
Transplantation immunology
Transplantation immunologyTransplantation immunology
Transplantation immunology
arunava choudhury
 
Transplantation immunology
Transplantation immunology Transplantation immunology
Immune tolerance
Immune toleranceImmune tolerance
Cells & organs of immune system
Cells & organs of immune systemCells & organs of immune system
Cells & organs of immune system
ArchanaSoni3
 
BCR
BCR BCR
B Cell Receptor & Antibody Production-Dr C R Meera
B Cell Receptor & Antibody Production-Dr C R MeeraB Cell Receptor & Antibody Production-Dr C R Meera
B Cell Receptor & Antibody Production-Dr C R Meera
Meera C R
 
Access to memory cells
Access to memory cellsAccess to memory cells
Access to memory cellseman youssif
 
T cell activation assay
T cell activation assayT cell activation assay
T cell activation assay
Creative Biolabs
 
Somatic hypermutation
Somatic hypermutationSomatic hypermutation
Somatic hypermutation
DESH BANDHU GANGWAR
 
Transplant immunology final ppt
Transplant immunology final pptTransplant immunology final ppt
Transplant immunology final ppt
DrTasneem Siddiqui
 
Severe combined immunodeficiency - SCID
Severe combined immunodeficiency - SCIDSevere combined immunodeficiency - SCID
Severe combined immunodeficiency - SCID
imam univarsity , college of medicine .
 
HLA and antigen presentation
HLA and antigen presentationHLA and antigen presentation
HLA and antigen presentation
Pooja Dhaka
 
Transplantation and tumor immunology
Transplantation and tumor immunologyTransplantation and tumor immunology
Transplantation and tumor immunologyBruno Mmassy
 

What's hot (20)

Immunological tolerance
Immunological toleranceImmunological tolerance
Immunological tolerance
 
Microcytotoxicity
MicrocytotoxicityMicrocytotoxicity
Microcytotoxicity
 
IMMUNE RESPONSE TO TUMORS
IMMUNE RESPONSE TO TUMORSIMMUNE RESPONSE TO TUMORS
IMMUNE RESPONSE TO TUMORS
 
Transplantation immunology
Transplantation immunology Transplantation immunology
Transplantation immunology
 
Tumor antigen
Tumor antigenTumor antigen
Tumor antigen
 
Transplantation immunology
Transplantation immunologyTransplantation immunology
Transplantation immunology
 
Transplantation immunology
Transplantation immunology Transplantation immunology
Transplantation immunology
 
Immune tolerance
Immune toleranceImmune tolerance
Immune tolerance
 
Cells & organs of immune system
Cells & organs of immune systemCells & organs of immune system
Cells & organs of immune system
 
Hla typing
Hla typingHla typing
Hla typing
 
BCR
BCR BCR
BCR
 
B Cell Receptor & Antibody Production-Dr C R Meera
B Cell Receptor & Antibody Production-Dr C R MeeraB Cell Receptor & Antibody Production-Dr C R Meera
B Cell Receptor & Antibody Production-Dr C R Meera
 
Access to memory cells
Access to memory cellsAccess to memory cells
Access to memory cells
 
T cell activation assay
T cell activation assayT cell activation assay
T cell activation assay
 
Somatic hypermutation
Somatic hypermutationSomatic hypermutation
Somatic hypermutation
 
Transplant immunology final ppt
Transplant immunology final pptTransplant immunology final ppt
Transplant immunology final ppt
 
Severe combined immunodeficiency - SCID
Severe combined immunodeficiency - SCIDSevere combined immunodeficiency - SCID
Severe combined immunodeficiency - SCID
 
HLA and antigen presentation
HLA and antigen presentationHLA and antigen presentation
HLA and antigen presentation
 
Transplantation and tumor immunology
Transplantation and tumor immunologyTransplantation and tumor immunology
Transplantation and tumor immunology
 
HLA
 HLA HLA
HLA
 

Viewers also liked

Transplantation
TransplantationTransplantation
Transplant example presentation
Transplant example presentationTransplant example presentation
Transplant example presentationspeedr8cer82
 
Transplantation by mateen irfansha
Transplantation  by mateen irfanshaTransplantation  by mateen irfansha
Transplantation by mateen irfansha
drmateenirfansha
 
Major Compatibility Complex & Transplantation
Major Compatibility Complex & TransplantationMajor Compatibility Complex & Transplantation
Major Compatibility Complex & Transplantation
Aman Ullah
 
Rejection cc 2014 jaipur
Rejection cc 2014 jaipurRejection cc 2014 jaipur
Rejection cc 2014 jaipur
Palepu BN Gopal
 
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
Kevin Jaglinski
 
Organ Transplantation and rejection
Organ Transplantation and rejectionOrgan Transplantation and rejection
Organ Transplantation and rejection
Inam Ullah Marwat
 
Major Histo compatibility Complex of Genes /certified fixed orthodontic cours...
Major Histo compatibility Complex of Genes /certified fixed orthodontic cours...Major Histo compatibility Complex of Genes /certified fixed orthodontic cours...
Major Histo compatibility Complex of Genes /certified fixed orthodontic cours...
Indian dental academy
 
Ethics of Organ Transplantation
Ethics of Organ TransplantationEthics of Organ Transplantation
Ethics of Organ Transplantation
Emma Light
 
3. transplantation
3. transplantation3. transplantation
3. transplantationBruno Mmassy
 
Antibody mediated rejection of solid organ allografts
Antibody mediated rejection of solid organ allograftsAntibody mediated rejection of solid organ allografts
Antibody mediated rejection of solid organ allografts
tashagarwal
 
Pharm immuno2 cells of the immune system
Pharm immuno2 cells of the immune systemPharm immuno2 cells of the immune system
Pharm immuno2 cells of the immune systemmmoney1
 
Organs transplant
Organs transplantOrgans transplant
Organs transplant
Alex Melgar
 
TRANSPLANTATION AND DONOR TYPES
TRANSPLANTATION AND  DONOR TYPESTRANSPLANTATION AND  DONOR TYPES
TRANSPLANTATION AND DONOR TYPES
manojsiddartha bolthajira
 
Antibody mediated rejection in kidney transplantation
Antibody mediated rejection in kidney transplantationAntibody mediated rejection in kidney transplantation
Antibody mediated rejection in kidney transplantationimrana tanvir
 
Organ transplantation heart & lung transplant
Organ transplantation           heart & lung transplantOrgan transplantation           heart & lung transplant
Organ transplantation heart & lung transplant
Dr Rajinder Dhaliwal
 
Principles of vascular anastomosis
Principles of vascular anastomosisPrinciples of vascular anastomosis
Principles of vascular anastomosis
Abdulsalam Taha
 

Viewers also liked (20)

15 Mhc
15 Mhc15 Mhc
15 Mhc
 
Transplant rejection
Transplant rejectionTransplant rejection
Transplant rejection
 
Transplantation
TransplantationTransplantation
Transplantation
 
Transplant example presentation
Transplant example presentationTransplant example presentation
Transplant example presentation
 
Transplantation by mateen irfansha
Transplantation  by mateen irfanshaTransplantation  by mateen irfansha
Transplantation by mateen irfansha
 
Mhc
MhcMhc
Mhc
 
Major Compatibility Complex & Transplantation
Major Compatibility Complex & TransplantationMajor Compatibility Complex & Transplantation
Major Compatibility Complex & Transplantation
 
Rejection cc 2014 jaipur
Rejection cc 2014 jaipurRejection cc 2014 jaipur
Rejection cc 2014 jaipur
 
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
 
Organ Transplantation and rejection
Organ Transplantation and rejectionOrgan Transplantation and rejection
Organ Transplantation and rejection
 
Major Histo compatibility Complex of Genes /certified fixed orthodontic cours...
Major Histo compatibility Complex of Genes /certified fixed orthodontic cours...Major Histo compatibility Complex of Genes /certified fixed orthodontic cours...
Major Histo compatibility Complex of Genes /certified fixed orthodontic cours...
 
Ethics of Organ Transplantation
Ethics of Organ TransplantationEthics of Organ Transplantation
Ethics of Organ Transplantation
 
3. transplantation
3. transplantation3. transplantation
3. transplantation
 
Antibody mediated rejection of solid organ allografts
Antibody mediated rejection of solid organ allograftsAntibody mediated rejection of solid organ allografts
Antibody mediated rejection of solid organ allografts
 
Pharm immuno2 cells of the immune system
Pharm immuno2 cells of the immune systemPharm immuno2 cells of the immune system
Pharm immuno2 cells of the immune system
 
Organs transplant
Organs transplantOrgans transplant
Organs transplant
 
TRANSPLANTATION AND DONOR TYPES
TRANSPLANTATION AND  DONOR TYPESTRANSPLANTATION AND  DONOR TYPES
TRANSPLANTATION AND DONOR TYPES
 
Antibody mediated rejection in kidney transplantation
Antibody mediated rejection in kidney transplantationAntibody mediated rejection in kidney transplantation
Antibody mediated rejection in kidney transplantation
 
Organ transplantation heart & lung transplant
Organ transplantation           heart & lung transplantOrgan transplantation           heart & lung transplant
Organ transplantation heart & lung transplant
 
Principles of vascular anastomosis
Principles of vascular anastomosisPrinciples of vascular anastomosis
Principles of vascular anastomosis
 

Similar to Pharm immuno14&15 cancer & transplantpor

Tumour immunology leture notes
Tumour immunology leture notesTumour immunology leture notes
Tumour immunology leture notesBruno Mmassy
 
Tumor antigens & cancer immunotherapy.pptx
Tumor antigens & cancer immunotherapy.pptxTumor antigens & cancer immunotherapy.pptx
Tumor antigens & cancer immunotherapy.pptx
Ragavi32
 
Anticancer immunity 2013
Anticancer immunity 2013Anticancer immunity 2013
Anticancer immunity 2013Elsa von Licy
 
Tumor immunology
Tumor immunologyTumor immunology
Tumor immunology
Promila Sheoran
 
Chapter 17 immunotherapy
Chapter 17 immunotherapyChapter 17 immunotherapy
Chapter 17 immunotherapy
Nilesh Kucha
 
Tumor immunity
Tumor immunityTumor immunity
Tumor immunity
madhursejwal
 
IMMUNE RESPONSE
IMMUNE RESPONSEIMMUNE RESPONSE
IMMUNE RESPONSE
ArunachaliOtaaku
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptx
Annie Annie
 
Cancer immunology.pptx
Cancer immunology.pptxCancer immunology.pptx
Cancer immunology.pptx
Annie Annie
 
cellular and molecular pharmacology - presentation
cellular and molecular pharmacology - presentationcellular and molecular pharmacology - presentation
cellular and molecular pharmacology - presentation
SIMRAN VERMA
 
MSI 825Tumor Immunology (1).pptx
MSI 825Tumor Immunology (1).pptxMSI 825Tumor Immunology (1).pptx
MSI 825Tumor Immunology (1).pptx
LilianNkinda
 
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial TumorsCancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
NeuroAcademy
 
11. tumour immunology.pptx
11. tumour immunology.pptx11. tumour immunology.pptx
11. tumour immunology.pptx
nedalalazzwy
 
Tumor Immunology
Tumor ImmunologyTumor Immunology
Tumor Immunology
ABED ALRAHMAN DAKKAK
 
Tumour Immunology
Tumour ImmunologyTumour Immunology
Tumour Immunology
dentistgneha
 
Tumour immunology
Tumour immunologyTumour immunology
Tumour immunology
dentistgneha
 
Cancer Immunotherapy and Gene Therapy
Cancer Immunotherapy and Gene TherapyCancer Immunotherapy and Gene Therapy
Cancer Immunotherapy and Gene Therapy
Arkaprava Roychaudhury
 

Similar to Pharm immuno14&15 cancer & transplantpor (20)

Tumourclasss
TumourclasssTumourclasss
Tumourclasss
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptx
 
Tumour immunology leture notes
Tumour immunology leture notesTumour immunology leture notes
Tumour immunology leture notes
 
Tumor antigens & cancer immunotherapy.pptx
Tumor antigens & cancer immunotherapy.pptxTumor antigens & cancer immunotherapy.pptx
Tumor antigens & cancer immunotherapy.pptx
 
Anticancer immunity 2013
Anticancer immunity 2013Anticancer immunity 2013
Anticancer immunity 2013
 
Tumor immunology
Tumor immunologyTumor immunology
Tumor immunology
 
Chapter 17 immunotherapy
Chapter 17 immunotherapyChapter 17 immunotherapy
Chapter 17 immunotherapy
 
Tumor immunity
Tumor immunityTumor immunity
Tumor immunity
 
IMMUNE RESPONSE
IMMUNE RESPONSEIMMUNE RESPONSE
IMMUNE RESPONSE
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptx
 
Cancer immunology.pptx
Cancer immunology.pptxCancer immunology.pptx
Cancer immunology.pptx
 
cellular and molecular pharmacology - presentation
cellular and molecular pharmacology - presentationcellular and molecular pharmacology - presentation
cellular and molecular pharmacology - presentation
 
MSI 825Tumor Immunology (1).pptx
MSI 825Tumor Immunology (1).pptxMSI 825Tumor Immunology (1).pptx
MSI 825Tumor Immunology (1).pptx
 
Tumor immunity
Tumor immunityTumor immunity
Tumor immunity
 
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial TumorsCancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
 
11. tumour immunology.pptx
11. tumour immunology.pptx11. tumour immunology.pptx
11. tumour immunology.pptx
 
Tumor Immunology
Tumor ImmunologyTumor Immunology
Tumor Immunology
 
Tumour Immunology
Tumour ImmunologyTumour Immunology
Tumour Immunology
 
Tumour immunology
Tumour immunologyTumour immunology
Tumour immunology
 
Cancer Immunotherapy and Gene Therapy
Cancer Immunotherapy and Gene TherapyCancer Immunotherapy and Gene Therapy
Cancer Immunotherapy and Gene Therapy
 

More from mmoney1

Pharm immuno3 &4 q innate immunity & complement
Pharm immuno3 &4 q innate immunity & complementPharm immuno3 &4 q innate immunity & complement
Pharm immuno3 &4 q innate immunity & complementmmoney1
 
Immuno1 overview
Immuno1 overviewImmuno1 overview
Immuno1 overviewmmoney1
 
Pharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiencyPharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiencymmoney1
 
Pharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiencyPharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiencymmoney1
 
Pharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiencyPharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiencymmoney1
 
Pharm immuno17-18 hypersensitivity por
Pharm immuno17-18 hypersensitivity porPharm immuno17-18 hypersensitivity por
Pharm immuno17-18 hypersensitivity pormmoney1
 
Pharm immuno9-11 portal
Pharm immuno9-11 portalPharm immuno9-11 portal
Pharm immuno9-11 portalmmoney1
 
Pharm immuno12 &13 tolerance & autoimmunity
Pharm immuno12 &13 tolerance & autoimmunityPharm immuno12 &13 tolerance & autoimmunity
Pharm immuno12 &13 tolerance & autoimmunitymmoney1
 
A&p 17 receptors and signaling of the ans
A&p 17 receptors and signaling of the ansA&p 17 receptors and signaling of the ans
A&p 17 receptors and signaling of the ansmmoney1
 
A&p 18 ans integration
A&p 18 ans integrationA&p 18 ans integration
A&p 18 ans integrationmmoney1
 
A&p 19 neural integration
A&p 19 neural integrationA&p 19 neural integration
A&p 19 neural integrationmmoney1
 
A&p 20 general sense
A&p 20 general senseA&p 20 general sense
A&p 20 general sensemmoney1
 
A&p 13 spinal cord
A&p 13 spinal cordA&p 13 spinal cord
A&p 13 spinal cordmmoney1
 
Helping patients with_change
Helping patients with_changeHelping patients with_change
Helping patients with_changemmoney1
 
Helping patients with_change
Helping patients with_changeHelping patients with_change
Helping patients with_changemmoney1
 
Helping patients with_change
Helping patients with_changeHelping patients with_change
Helping patients with_changemmoney1
 
Helping patients with_change
Helping patients with_changeHelping patients with_change
Helping patients with_changemmoney1
 
Helping patients with_change
Helping patients with_changeHelping patients with_change
Helping patients with_changemmoney1
 
Conflict resolution
Conflict resolutionConflict resolution
Conflict resolutionmmoney1
 
Pharm immuno5-6serv adaptive immune response ag-ab
Pharm immuno5-6serv adaptive immune response ag-abPharm immuno5-6serv adaptive immune response ag-ab
Pharm immuno5-6serv adaptive immune response ag-abmmoney1
 

More from mmoney1 (20)

Pharm immuno3 &4 q innate immunity & complement
Pharm immuno3 &4 q innate immunity & complementPharm immuno3 &4 q innate immunity & complement
Pharm immuno3 &4 q innate immunity & complement
 
Immuno1 overview
Immuno1 overviewImmuno1 overview
Immuno1 overview
 
Pharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiencyPharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiency
 
Pharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiencyPharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiency
 
Pharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiencyPharm immuno19 immunodeficiency
Pharm immuno19 immunodeficiency
 
Pharm immuno17-18 hypersensitivity por
Pharm immuno17-18 hypersensitivity porPharm immuno17-18 hypersensitivity por
Pharm immuno17-18 hypersensitivity por
 
Pharm immuno9-11 portal
Pharm immuno9-11 portalPharm immuno9-11 portal
Pharm immuno9-11 portal
 
Pharm immuno12 &13 tolerance & autoimmunity
Pharm immuno12 &13 tolerance & autoimmunityPharm immuno12 &13 tolerance & autoimmunity
Pharm immuno12 &13 tolerance & autoimmunity
 
A&p 17 receptors and signaling of the ans
A&p 17 receptors and signaling of the ansA&p 17 receptors and signaling of the ans
A&p 17 receptors and signaling of the ans
 
A&p 18 ans integration
A&p 18 ans integrationA&p 18 ans integration
A&p 18 ans integration
 
A&p 19 neural integration
A&p 19 neural integrationA&p 19 neural integration
A&p 19 neural integration
 
A&p 20 general sense
A&p 20 general senseA&p 20 general sense
A&p 20 general sense
 
A&p 13 spinal cord
A&p 13 spinal cordA&p 13 spinal cord
A&p 13 spinal cord
 
Helping patients with_change
Helping patients with_changeHelping patients with_change
Helping patients with_change
 
Helping patients with_change
Helping patients with_changeHelping patients with_change
Helping patients with_change
 
Helping patients with_change
Helping patients with_changeHelping patients with_change
Helping patients with_change
 
Helping patients with_change
Helping patients with_changeHelping patients with_change
Helping patients with_change
 
Helping patients with_change
Helping patients with_changeHelping patients with_change
Helping patients with_change
 
Conflict resolution
Conflict resolutionConflict resolution
Conflict resolution
 
Pharm immuno5-6serv adaptive immune response ag-ab
Pharm immuno5-6serv adaptive immune response ag-abPharm immuno5-6serv adaptive immune response ag-ab
Pharm immuno5-6serv adaptive immune response ag-ab
 

Recently uploaded

Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
Tamralipta Mahavidyalaya
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
MIRIAMSALINAS13
 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Po-Chuan Chen
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 

Recently uploaded (20)

Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 

Editor's Notes

  1. Fig. 10-1
  2. CALLA: Common Acute Lymphoblastic Leukemia Antigen (CD10) sIgM – Signal IgM as sign of maturity of B cell
  3. Fig 20-5
  4. Fig. 20.6 Tc cells taken from a mouse immunized with a tum- variant tumor: They kill tumor cells coated with a peptide from the tum- gene sequence They do not kill tumor cells coated with the homologous peptide from the parental tumor The two peptides differ in one amino acid
  5. vi. Role in immunosurveillance (T cell-deficient nude mice w/o high incidence of spontaneous tumors
  6. cachectin ka-kek c tin A polypeptide cytokine, produced by endotoxin-activated macrophages , which has the ability to modulate adipocyte metabolism, lyse tumor cells in vitro, and induce hemorrhagic necrosis of certain transplantable tumors in vivo. Syn: tumor necrosis factor. Origin [G. kakos, bad, + hexis, condition of body] (SEE ABBAS, P. 367/68)
  7. glycocalyx A PAS-positive filamentous coating on the apical surface of certain epithelial cells, composed of carbohydrate moieties of proteins that protrude from the free surface of the plasma membrane. Origin [glyco- + G. kalyx, husk, shell] PAS para-aminosalysylic acid.periodic acid-Schiff stain
  8. Fig. 20-12 From Roitt et al
  9. GM-CSF (granulocyte, macrophage-colony stimulating factor). idiotype id cT - b -t U p Collection of idiotopes within the variable region that confers on an immunoglobulin molecule an antigenic “individuality” and is frequently a unique attribute of a given antibody in a given animal. It is the product of a limited number of B lymphocyte clones ; also found on the T-cell receptor . See: idiotope [single antigenic determinant of an idiotype] . Origin [idio- + G. typos, model] idiotope id cT - b t b p Single antigenic determinant of an idiotype. See Also: idiotypic antigenic determinant. Syn: idiotypic antigenic determinant. Origin [idio- + -tope] set of idiotopes
  10. Fig 10-5 Tumor-specific immune responses may be stimulated by vaccinating with host dendritic cells that have been pulsed (incubated) with tumor antigens (A) or with plasmids containing complementary DNAs encoding tumor antigens that are injected directly into patients or used to transfect dendritic cells (B) or by vaccinating with tumor cells transfected with genes encoding B7 costimulators or the T cell growth factor interleukin-2 (C)
  11. FIG. 20.23, ROITT, ET AL
  12. FIG 20-18
  13. FIG. 20-19: ROITT ET AL -98
  14. Rg. 20.20 Biological response modifiers (BRMs) are used to enhance immune responses to turnours and fall into four major groups. Broadly speaking, bacterial products have adjuvant effects on macrophages (see Chapters 17 and 19); a variety of synthetic polymers, nucleotides and polynucleotides induce IFN production and release; the cytokines administered directly act on macrophages and NK cells, and a variety of hormones including the thymic hormones can be used to enhance T-cell function. (MVE = maleic anhydride divinyl ether; TNF = tumour necrosis factor; poly 1: C = polyinosinic-polycytidylic acid.)
  15. Fig 20.21 Genetically engineered chimeric Abs with human Fc portion attached to mouse Fab 2 reduce the risk of an immune response to the mAb Human Fc will also recruit human effector mechanisms Molecules that can be coupled to mAbs Toxins Cytotoxic drugs or enzymes capable of activating drugs Radioactive isotopes
  16. Bone marrow containing tumor cell can be purged using mAbs and complement, Ab-toxin conjugates or Ab coupled to magnetic beads Store purged marrow Treat patient with radiation and chemotherapy Treat purged marrow with anti-tumor Ab Return bone marrow to patient Therapy results are encouraging in leukemia and lymphoma patients who where not helped by conventional therapy
  17. 1- Circulating tumor markers are diagnostic: i.  -fetoprotein  hepatic carcinoma ii. Carcinoembryonic Ag (CEA)  colorectal carcinoma iii. GM1 monosialoganglioside in 96% of patients with pancreatic carcinoma 2- Monoclonal Ab to tumor surface antigens can provide a basis for imaging. Good targets include: i. F19 glycoprotein on reactive stromal fibroblasts ii. Certain tumor mucins/epithelial cancers(Thomson-Friedenreich or T antigen) iii. Cytokeratin on carcinoma cells 3- Detection of bone marrow micrometastasis using immunocytochemistry techniques provides information on: i. Prognosis ii. Efficacy of a new therapy iii. Eventual recurrence of treated cancer
  18. NORMAL RANGE = 8 NG/ML
  19. Parents: AA x BB Gametes: A, B F1: AB A ---to-  A & B --  B Accepted A ----  B and B ---  A Rejection 3. (Parent) A --------  F1 Hybrid: AB Result: Graft accepted because we introduce A antigen from parent to F1 recipient who has the same antigen A. No immune response needed The reverse is rejected: AB (F1) -----------  A Parent AB (F1) -----------  B Parent Result: Rejection because the recipient A does not have B antigen. Therefore, it will have immune reaction with Ab and T cells against B antigens; and Rejection because the recipient B does not have A antigen. Therefore, it will have immune reaction with Ab and T cells against A antigens. Fourth Law: Parents: AA x BB Gametes: A, B F1: AB Gametes: (A, B) x (A, B) F2: AA, 2AB, BB Transplant from any F2 individual (AA, AB, or BB) ---------  F1 Hybrid (AB) must lead to acceptance because AB has all transplanted antigens Conclusion: Genes (and antigens) of each F2 individual are represented in F1 individuals. Thus, F1 individuals have no antibodies against F2 individuals and higher generation.
  20. Fig. 10-6
  21. Fig 10-7
  22. Fig 10-8
  23. intimal Relating to the intima or inner coat of a vessel. DTH: delayed type hypersensitivity
  24. III. Rejections A. Host-versus-Graft Rejection 1. First Set Rejection 2. Second Set Rejection (Acute) 3. Hyperacute Rejection 4. Chronic Graft Rejection
  25. 6. Characteristics: i. Acute : epithelial cell necrosis in GI, liver and skin ii. Chronic : fibrosis and atrophy of GI, liver and skin; no epithelial necrosis